Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.40 |
| ▸ | PDE2A | O00408 | 5/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.37 |
| ▸ | PDE5A | O76074 | 4/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | HTR2B | P41595 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184013 | 0.93 | MAPT (0.42) | MAPTALDH1A1GAAPTGER2CYP11B2 | |
| SCHEMBL16184012 | 0.89 | ALDH1A1 (0.43) | MAPTALDH1A1GAAPTGER2CYP11B2 | |
| SCHEMBL16184015 | 0.88 | ALDH1A1 (0.41) | MAPTALDH1A1GAAPTGER2CYP11B2 | |
| SCHEMBL16183995 | 0.87 | ALDH1A1 (0.45) | MAPTALDH1A1GAAPTGER2CYP11B2 | |
| SCHEMBL16183376 | 0.84 | CYP11B2 (0.46) | MAPTALDH1A1GAACYP11B2PDE5A | |
| SCHEMBL16183391 | 0.82 | CYP11B2 (0.46) | MAPTALDH1A1GAACYP11B2PDE5A | |
| SCHEMBL16183415 | 0.82 | CYP11B2 (0.41) | MAPTALDH1A1GAACYP11B2HTR2A | |
| SCHEMBL16183406 | 0.82 | MAPT (0.46) | MAPTALDH1A1GAAPTGER2CYP11B2 | |
| SCHEMBL16184734 | 0.81 | MAPT (0.45) | MAPTALDH1A1GAACYP11B2PDE2A | |
| SCHEMBL16184732 | 0.81 | CYP1A2 (0.54) | MAPTALDH1A1GAAPDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | MAPT 509/4885ALDH1A1 1687/4885GAA 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.